Real World Data (RWD) Market Report 2026

The real world data (rwd) market size has grown rapidly in recent years. It will grow from $2.01 billion in 2025 to $2.34 billion in 2026 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to growth of electronic health record adoption, expansion of healthcare digitization initiatives, rising demand for post-market drug surveillance, increasing availability of claims and registry data, early use of observational studies in healthcare research.

The real world data (rwd) market size is expected to see rapid growth in the next few years. It will grow to $4.21 billion in 2030 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to increasing regulatory acceptance of real-world evidence, rising focus on personalized medicine, expansion of AI-driven healthcare analytics, growing investments in digital health infrastructure, increasing use of rwd in value-based care models. Major trends in the forecast period include increasing adoption of real-world evidence in drug approvals, rising integration of multi-source healthcare datasets, growing use of wearable and patient-generated data, expansion of advanced data analytics platforms, enhanced focus on data standardization and interoperability.

The rising adoption of electronic health records is expected to drive the expansion of the real-world data (RWD) market in the coming years. Electronic health records are digital versions of patients’ medical charts that store and manage comprehensive health information to enhance care coordination and support clinical decision-making. This growing adoption is mainly driven by the need to improve patient care and safety, as electronic health records allow accurate, real-time access to patient data, minimize medical errors, and strengthen clinical decision-making. Real-world data complements electronic health records by offering insights into patient outcomes and the effectiveness of treatments in routine clinical practice, enabling more personalized and evidence-based care. For example, in November 2023, according to NHS England, a UK-based government health authority, 90% of NHS hospital trusts had implemented an Electronic Patient Record (EPR) system, reaching the national adoption target ahead of schedule. As a result, the increasing use of electronic health records is supporting the growth of the real-world data market.

Leading companies in the real-world data (RWD) sector are prioritizing the development of innovative solutions, such as integrated analysis-ready datasets, to simplify evidence generation and speed up clinical decision-making. An integrated analysis-ready dataset is a cleaned, standardized, and combined compilation of data from multiple sources that can be used for analysis immediately, without the need for further preprocessing. For example, in January 2025, Carelon Research, Inc., a US-based healthcare research company, introduced Carelon Real World Data, a comprehensive, analysis-ready dataset aimed at enhancing healthcare evidence generation. This dataset provides a complete, analysis-ready resource that merges closed claims with electronic health records, offering detailed insights on patients, providers, and payers. It also incorporates enriched information on oncology, lab results, race and ethnicity, and social determinants of health. Developed based on decades of research, the dataset is customized to address specific research needs and supports evidence generation across all therapeutic areas for life sciences teams.

In December 2023, Finland-based BC Platforms, a company specializing in building data networks for the life sciences sector, acquired Medexprim for an undisclosed amount. Through this acquisition, BC Platforms aims to expand its real-world data capabilities, particularly by integrating Medexprim’s clinical imaging expertise, thereby enhancing their ability to deliver comprehensive, multi-modal healthcare data solutions for research and innovation. Medexprim is a France-based software company that provides real-world data and real-world evidence solutions.

Major companies operating in the real world data (rwd) market are Oracle Corporation, IQVIA Holdings Inc., ICON Public Limited Company, Syneos Health Inc., Parexel International Corporation, Revvity Inc., SAS Institute Inc., Datavant Inc., Palantir Technologies Inc., Tempus Labs Inc., Clarivate Plc, Flatiron Health Inc., Tempus Labs Inc., Clinigen Group plc, Komodo Health Inc., Aetion Inc., TriNetX LLC, Clarify Health Solutions Inc., Verana Health Inc., Evidation Health Inc., OM1 Inc., HealthVerity Inc., Pulse Infoframe Inc.

North America was the largest region in the real world data (RWD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the real world data (rwd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the real world data (rwd) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The real-world data (RWD) market includes revenues earned by entities by providing services, such as data collection services, data aggregation and integration, data analytics and insights, data licensing and subscription, and real-time monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.